rdf:type |
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0079083,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0332157,
umls-concept:C0439849,
umls-concept:C0600688,
umls-concept:C0871261,
umls-concept:C1140680,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
pubmed:issue |
6
|
pubmed:dateCreated |
1993-6-29
|
pubmed:abstractText |
To determine (1) the impact of cyclophosphamide 600 mg/m2 on previously defined relationships between carboplatin area under the plasma concentration versus time curve (AUC) and indices of toxicity and response in women with advanced ovarian cancer; and (2) the relationships between indices of cumulative drug exposure and clinical outcomes.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0732-183X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1156-64
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8501502-Adult,
pubmed-meshheading:8501502-Aged,
pubmed-meshheading:8501502-Aged, 80 and over,
pubmed-meshheading:8501502-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8501502-Carboplatin,
pubmed-meshheading:8501502-Cyclophosphamide,
pubmed-meshheading:8501502-Dose-Response Relationship, Drug,
pubmed-meshheading:8501502-Female,
pubmed-meshheading:8501502-Humans,
pubmed-meshheading:8501502-Leukopenia,
pubmed-meshheading:8501502-Middle Aged,
pubmed-meshheading:8501502-Ovarian Neoplasms,
pubmed-meshheading:8501502-Thrombocytopenia
|
pubmed:year |
1993
|
pubmed:articleTitle |
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
|
pubmed:affiliation |
Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore 21201.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|